Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Verrica Pharmaceuticals (VRCA) Other Operating Expenses (2021 - 2025)

Verrica Pharmaceuticals has reported Other Operating Expenses over the past 5 years, most recently at $1.6 million for Q4 2025.

  • Quarterly results put Other Operating Expenses at $1.6 million for Q4 2025, up 132.63% from a year ago — trailing twelve months through Dec 2025 was $3.7 million (up 30.61% YoY), and the annual figure for FY2025 was -$246000.0, down 196.39%.
  • Other Operating Expenses for Q4 2025 was $1.6 million at Verrica Pharmaceuticals, up from $1.1 million in the prior quarter.
  • Over the last five years, Other Operating Expenses for VRCA hit a ceiling of $13.6 million in Q4 2021 and a floor of $62000.0 in Q4 2022.
  • Median Other Operating Expenses over the past 5 years was $437000.0 (2025), compared with a mean of $1.4 million.
  • Biggest five-year swings in Other Operating Expenses: crashed 99.55% in 2022 and later soared 4430.65% in 2023.
  • Verrica Pharmaceuticals' Other Operating Expenses stood at $13.6 million in 2021, then crashed by 99.55% to $62000.0 in 2022, then soared by 4430.65% to $2.8 million in 2023, then plummeted by 74.8% to $708000.0 in 2024, then skyrocketed by 132.63% to $1.6 million in 2025.
  • The last three reported values for Other Operating Expenses were $1.6 million (Q4 2025), $1.1 million (Q3 2025), and $494000.0 (Q2 2025) per Business Quant data.